Recently, Suzhou Zhonghua Pharmaceutical's Huaroning® (Ketoprofen Sustained-Release Tablets) was officially approved for market release by the National Medical Products Administration (NMPA) (Approval No. H20255883) and is considered to have passed the consistency evaluation.

Theobromine, as a type of non-specific phosphodiesterase inhibitor, has multiple pharmacological effects, including enhancing red blood cell deformability,

inhibiting platelet aggregation, dilating blood vessels, and anti-inflammatory actions. It has been included in the national medical insurance Category B list. This drug is mainly used to treat peripheral vascular diseases, such as symptoms like intermittent claudication caused by chronic peripheral arterial occlusive disease, and can also be used to improve posterior circulation after ischemic cerebrovascular disease.

Clinically proven efficacy: recommended by multiple guidelines and consensus statements

Ketocaffeine sustained-release tablets have the advantages of comprehensively improving microcirculation, long-acting release, suitability for a wide range of people, and high safety. They have been explicitly recommended in multiple multidisciplinary guidelines and consensus statements, including the "Chinese Guidelines for the Diagnosis and Treatment of Vascular Cognitive Impairment," the "Expert Consensus on the Management of Post-Stroke Cognitive Impairment," and the "China Diabetes Prevention and Treatment Guidelines (2024 Edition)."

Product Technology and Quality: Controlling from the Source to Ensure Long-Term Effectiveness

Hualoning® relies on meticulous craftsmanship and strict quality control to create the core advantages of its products.Precise raw material control, more stable release: By accurately controlling the particle size of raw materials, the release behavior of the drug within the sustained-release matrix is effectively optimized, significantly reducing the risk of burst release and ensuring a smooth and consistent release profile both in vitro and in vivo.

Import key raw and auxiliary materials, quality as the foundation: Imported raw materials and key sustained-release materials have higher quality standards and excellent batch consistency, ensuring reliable and stable product quality from the source.

Good stability and convenient storage and transportation: The product demonstrates excellent stability in both accelerated and long-term sample studies, with no significant changes in key quality attributes. It only requires storage at room temperature, providing great convenience for long-term patient use and distribution logistics.

As a pharmaceutical company with the vision of being "a trusted health enterprise in the Chinese-speaking world," Suzhou Sinochem Pharmaceuticals is 

committed to integrating the values of "innovation, health, care, and passion" into product development and disease management services. The company 

not only focuses on drug treatments for specific diseases but also emphasizes overall patient health, providing multidimensional health solutions to help 

improve the overall quality of life for patients with chronic diseases.

The successful launch of Valoning® marks another significant achievement of Suzhou Sinochem Pharmaceuticals in the ongoing development of cardiovascular 

and cerebrovascular treatments. With the accelerated aging of our society, the incidence of cerebrovascular and peripheral vascular diseases continues to rise. 

We believe that Valoning®, with its proven clinical efficacy and broad mechanism of action, will bring long-term health benefits to more patients, helping them 

enjoy a relaxed and healthy life!